Evidence map›Paper›PMID 35044481›Full record

ReviewDer Nervenarzt2022

[Relevance of COMT inhibitors in the treatment of motor fluctuations].

Wolfgang H Jost, Carsten Buhmann, Joseph Classen, Karla Eggert, Zacharias Kohl, Tiago Outeiro, Lars Tönges, Dirk Woitalla, Heinz Reichmann

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Nervenarzt, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. The Treatment of Older Patients with Parkinson's Disease.Deutsches Arzteblatt international · 2025
    Review
  3. Sublingual apomorphine in the treatment of Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2024
    Review
  4. Article
  5. Role of dopamine agonists in Parkinson's disease therapy.Journal of neural transmission (Vienna, Austria : 1996) · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Wolfgang H JostParkinson-Klinik Ortenau, Kreuzbergstr. 12-16, 77709, Wolfach, Deutschland. w.jost@parkinson-klinik.de.
Carsten BuhmannKlinik und Poliklinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg-Eppendorf, Deutschland.
Joseph ClassenKlinik und Poliklinik für Neurologie, Universitätsklinikum Leipzig, Leipzig, Deutschland.
Karla EggertKlinik für Neurologie, Universität Marburg, Marburg, Deutschland.
Zacharias KohlKlinik und Poliklinik für Neurologie, Universität Regensburg, Regensburg, Deutschland.
Tiago OuteiroExperimentelle Neurodegeneration, Universitätsmedizin Göttingen, Göttingen, Deutschland.
Lars TöngesNeurologische Klinik der Ruhr-Universität Bochum, St. Josef-Hospital, Klinikum der Ruhr-Universität Bochum, Bochum, Deutschland.
Dirk WoitallaKlinik für Neurologie, St. Josef-Krankenhaus, Essen-Kupferdreh, Deutschland.
Heinz ReichmannKlinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Deutschland.
Klinik und Poliklinik für Neurologie · DEParkinson-Klinik Ortenau · DEPhilipps University of Marburg · DESt. Josef-Hospital · DESt. Josef Krankenhaus · DEUniversitätsmedizin Göttingen · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Catechol O‑methyltransferase (COMT) inhibitors have been established in the treatment of Parkinson's disease for more than 20 years. They are considered the medication of choice for treating motor fluctuations. The available COMT inhibitors, entacapone, opicapone and tolcapone, differ pharmacokinetically in terms of their half-lives with implications for the dose frequency, in their indication requirements and in their spectrum of side effects, including diarrhea and yellow discoloration of urine. Many patients with motor fluctuations are currently not treated with COMT inhibitors and are, therefore, unlikely to receive individually optimized drug treatment. This manuscript summarizes the results of a working group including several Parkinson's disease experts, in which the value of COMT inhibitors was critically discussed.

Indexed as

Catechol O-Methyltransferase InhibitorsParkinson DiseaseAntiparkinson AgentsCatechol O-MethyltransferaseHumansLevodopaTolcaponeAntiparkinson AgentsCatechol O-MethyltransferaseCatechol O-Methyltransferase InhibitorsCOMT protein, humanLevodopaTolcaponeEntacaponeMotor fluctuationsOpicaponeParkinson’s diseaseTolcapone

Identifiers

PMID35044481
OpenAlexW4205301217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.